Loading search results
Understanding the Perceived Influence of Childhood Cancer and NF1 on the Parents' Marital/Partner Relationship: A Descriptive Study
Sponsor study identifier
Secondary identifiers
observational
262
2 countries
3
Study Start
September 13, 2012
Actual (reported)Primary Completion
December 7, 2020
Actual (reported)Study Completion
December 7, 2020
Actual (reported)Background: \- Serious illnesses like cancer or Neurofibromatosis Type 1 (NF1), can cause high levels of stress in a family. When a child is diagnosed with cancer or NF1, parents face numerous stressors, each of which can strain relationships. Many parents struggle to effectively cope with the changes in parenting roles that often accompany treatment of childhood cancer or NF1. How parents cope with this stress can influence whether the relationship is strengthened or weakened. Stress levels can also affect the care of the child who has cancer or NF1. Researchers want to better understand the critical time points and events during the child s treatment when the relationship becomes most stressed and/or strengthened. Objectives: \- To study how stress affects the relationship between parents who have a child with cancer or Neurofibromatosis Type 1 (NF1). Eligibility:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 7, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 13, 2012
Actual (reported)October 6, 2012
Actual (reported)October 10, 2012
Actual (reported)December 7, 2020
Actual (reported)December 7, 2020
Actual (reported)Stress impact communication
To explore whether the stress associated with having a child with cancer or NF1 is perceived to impact the communication between partners.
3 months
Dyadic coping
3 months
Stressful timepoints
3 months
Perception comparison
Must have been in a partnership at the time child was diagnosed with cancer \& must have been diagnosed at least 3 months prior to enrollment on this study \& be currently receiving treatment
Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
Participants must have been in a partnership at the time the child was diagnosed with cancer or NFl. At least one participant must be the biological/legal parent of the child; the partner may or may not be a biological/legal parent. Divorced parents who separated or divorced during or after the child's treatment can participate in this study.@@@@@@
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Alberta's Children's Hospital Hematology/Oncology/Transplant Program
Alberta, T2L 2A6, Canada
Lori Wiener, Ph.D.
National Cancer Institute (NCI)
262 participants (actual enrollment reported by the registry).
First Submitted
October 6, 2012
First Posted
October 10, 2012
Study Start
September 13, 2012
Actual (reported)3 months
Contact the study team to confirm eligibility.
Primary Completion
December 7, 2020
Actual (reported)Study Completion
December 7, 2020
Actual (reported)Last Updated
July 31, 2024
Record last verified: 2024-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: